In this multicenter retrospective study, we report for the first time clinical features, response to MET inhibitors and outcome of 42 metastatic EGFR-mutated NSCLC patients with MET amplification or MET overexpression, as assessed on a post-progression re-biopsy. The gene discussed is MET; the disease is non-small cell lung carcinoma.